Zepbound Geriatric (65+) Caregiver Administration Guidance

Print or save as PDF

Does the Zepbound dose change at 65 or older?

Zepbound's label sets out a single escalation schedule for every adult. Treatment starts at 2.5 mg injected subcutaneously once a week for 4 weeks; the label calls 2.5 mg an initiation dose and states it is not approved as a maintenance dose. After 4 weeks the dose goes to 5 mg, and it can then rise in 2.5 mg steps, with at least 4 weeks on each dose [1]. The label says to follow that escalation for all indications and to choose the maintenance dose based on response and tolerability, moving to a lower maintenance dose if a higher one is not tolerated [1].

Maintenance for weight reduction is 5, 10 or 15 mg once weekly; for obstructive sleep apnea it is 10 or 15 mg; the maximum is 15 mg weekly [1]. Nothing in the label's dosing section creates a separate schedule for adults 65 and older [1], and the label calls for no dose adjustment in renal or hepatic impairment [1].

Training the caregiver before the first injection

Zepbound comes as a vial, a prefilled single-dose pen, or a single-patient-use KwikPen. The label says to tell patients and caregivers which presentation they will receive and to train them on proper injection technique for that specific presentation before the first dose. If a different presentation is prescribed later, the label points to the Instructions for Use for the new one [1].

After training, a patient may self-inject if the prescriber determines it can be done properly. One exception is written into the label: the KwikPen is not recommended for self-administration by people who are visually impaired [1]. The label also states that a KwikPen must never be shared between patients, even if the needle is changed [1].

Where and when to give the injection

The approved sites are the abdomen, the thigh, and the back of the upper arm. The upper arm is injected by another person, which is usually where a caregiver comes in. The Zepbound label says to rotate injection sites, and that the injection can be given at any time of day, with or without food [1]. Exposure to tirzepatide is similar whether it goes into the abdomen, thigh or upper arm [1].

The fine detail of technique, such as how the device is held, how long it stays in place and how the pen is prepared, differs between the vial, the single-dose pen and the KwikPen. The label directs caregivers to the Instructions for Use for the presentation in hand [1].

Missed doses and moving the weekly day

If a dose is missed, the label says to give it as soon as possible within 4 days (96 hours) of the missed time. If more than 4 days have passed, the dose is skipped and the next one is given on the regularly scheduled day; in either case the usual weekly schedule then resumes [1]. The day of the week can be changed as long as the gap between two doses is at least 3 days (72 hours) [1].

What to watch for in an older adult

In the pooled weight-management trials (958 patients on placebo, 630 on 5 mg, 948 on 10 mg, 941 on 15 mg), nausea occurred in 25%, 29% and 28% of Zepbound-treated patients versus 8% on placebo; diarrhea in 19%, 21% and 23% versus 8%; vomiting in 8%, 11% and 13% versus 2%; and constipation in 17%, 14% and 11% versus 5% [1]. Any gastrointestinal adverse reaction was reported by 56% of patients on every Zepbound dose versus 30% on placebo, and most nausea, vomiting and diarrhea happened during dose escalation and eased over time [1]. Those trials had a mean age of 47 years, so they describe a younger population than the one a caregiver is usually looking after [1].

The label's acute kidney injury warning is relevant when vomiting or diarrhea could lead to dehydration. Postmarketing reports describe acute kidney injury, sometimes requiring dialysis, and most of the reported events occurred in patients who had gastrointestinal reactions leading to dehydration such as nausea, vomiting or diarrhea [1]. The label asks prescribers to monitor renal function in patients reporting reactions that could lead to volume depletion, especially during initiation and dose escalation [1].

Dizziness was reported in 4% to 5% of Zepbound-treated patients versus 2% on placebo, and hypotension in 1.6% versus 0.1% [1]. Hypotension was more frequent in patients also taking antihypertensive medication (2.2%) than in those who were not (1.2%) [1]. Injection site reactions (6% to 8% versus 2%) and fatigue (5% to 7% versus 3%) are also listed [1].

When Zepbound is added to insulin or an insulin secretagogue such as a sulfonylurea, the label says to consider lowering the dose of the insulin or secretagogue to reduce the risk of hypoglycemia [1]. In SURMOUNT-2, which enrolled adults with type 2 diabetes, hypoglycemia with glucose below 54 mg/dL occurred in 10.3% of patients taking a sulfonylurea versus 2.1% of those not taking one [1].

Serious warnings that apply at any age

The boxed warning covers thyroid C-cell tumors. In rats, tirzepatide caused dose- and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures; whether it causes them in humans, including medullary thyroid carcinoma, is unknown. Zepbound is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2, and the label says to counsel patients about symptoms of thyroid tumors: a mass in the neck, difficulty swallowing, difficulty breathing, or persistent hoarseness [1]. Routine calcitonin monitoring or thyroid ultrasound is of uncertain value for early detection [1].

Severe gastrointestinal reactions were reported in 1.7% of patients on 5 mg, 2.5% on 10 mg and 3.1% on 15 mg versus 1% on placebo, and the drug is not recommended in people with severe gastroparesis [1]. For acute pancreatitis, 0.2% of Zepbound-treated patients had an adjudicated event in the pooled weight-management trials versus 0.2% on placebo; the label says to discontinue Zepbound if pancreatitis is suspected, and describes the warning signs as persistent or severe abdominal pain, sometimes radiating to the back, which may or may not come with nausea or vomiting [1].

Gallbladder events were more frequent with Zepbound in the same pool: cholelithiasis 1.1% versus 1%, cholecystitis 0.7% versus 0.2%, and cholecystectomy 0.2% versus none on placebo [1]. Serious hypersensitivity reactions occurred in 0.1% of Zepbound-treated patients versus none on placebo, and anaphylaxis and angioedema have been reported after marketing [1]. Pulmonary aspiration has been reported in patients on GLP-1 receptor agonists during elective surgery or deep sedation, and the label tells patients to inform healthcare providers of any planned surgery or procedure [1].

Weight loss, lean mass, and the 65+ question

The body-composition data come from a 160-person substudy of SURMOUNT-1, with DXA scans at baseline and week 72 (124 participants pooled across tirzepatide doses, 36 on placebo; mean weight 102.5 kg). Body weight fell 21.3%, fat mass 33.9% and lean mass 10.9% with tirzepatide, versus 5.3%, 8.2% and 2.6% with placebo [2]. About 75% of the weight lost was fat mass and about 25% lean mass, for both tirzepatide and placebo. Post hoc subgroup analyses by sex, age (including 65 and older) and weight-loss tertile were consistent across most subgroups [2]. It was a small substudy, and DXA does not separate muscle from other lean tissue [2]. A review of obesity drug treatment in older adults notes that concise guidelines for this age group are not available and that more trials are needed with geriatric endpoints such as muscle mass preservation, bone quality and fat distribution [3].

Sharps disposal

The FDA says used sharps should be placed in an FDA-cleared sharps container immediately; if none is available, a heavy-duty plastic household container such as a laundry detergent container can be used. Loose needles and other sharps should never go into household trash, recycling bins or the toilet [5]. If someone is accidentally stuck by a used needle, the FDA advises washing the area right away with soap and water or a skin disinfectant and seeking immediate medical attention [5].